PCM
XENT

Palisade Capital Management’s Intersect ENT, Inc XENT Stock Holding History

Palisade Capital Management’s Portfolio XENT Stock Details XENT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-45,200
Closed -$716K – 548
2016
Q3 		$716K Sell
45,200
-16,300
-27% -$245K 0.03% 458
2016
Q2 		$795K Sell
61,500
-173,573
-74% -$2.72M 0.03% 432
2016
Q1 		$4.47M Buy
235,073
+45,227
+24% +$819K 0.15% 214
2015
Q4 		$4.27M Buy
189,846
+17,227
+10% +$341K 0.14% 231
2015
Q3 		$4.04M Buy
+172,619
New +$4.76M 0.12% 260

Other funds holding XENT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Palisade Capital Management's XENT Position: Q4 2016 in Review

Palisade Capital Management sold out of Intersect ENT, Inc (XENT) in Q4 2016, closing a stake of 45,200 shares — an estimated $716K sold.

Palisade Capital Management first reported a position in XENT in Q3 2015 and held it in 5 quarters. The position peaked at $4.47M in Q1 2016. 104 funds tracked by Wall St. Rank hold XENT as of Q4 2016.

  • Palisade Capital Management reported no remaining Intersect ENT, Inc position as of Q4 2016 after selling out during the quarter.
  • Palisade Capital Management sold 45,200 Intersect ENT, Inc shares in Q4 2016, an estimated $716K.
  • Palisade Capital Management first reported a position in Intersect ENT, Inc in Q3 2015 and held it in 5 quarters.
  • Palisade Capital Management's Intersect ENT, Inc position peaked at $4.47M in Q1 2016.
  • 104 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q4 2016.

Based on Palisade Capital Management's 13F filing for Q4 2016, filed 31 Jan 2017.